Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000725751 | SCV000339160 | pathogenic | not provided | 2016-02-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001034690 | SCV000638333 | pathogenic | GNE myopathy; Sialuria | 2023-05-21 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs745517517, gnomAD 0.006%). This sequence change creates a premature translational stop signal (p.Arg90*) in the GNE gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GNE are known to be pathogenic (PMID: 24027297). This variant has not been reported in the literature in individuals affected with GNE-related conditions. For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 285936). |
Revvity Omics, |
RCV000725751 | SCV003824619 | pathogenic | not provided | 2022-06-24 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000593290 | SCV004199389 | pathogenic | GNE myopathy | 2023-11-27 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005044535 | SCV005682232 | pathogenic | GNE myopathy; Sialuria; Thrombocytopenia 12 with or without myopathy | 2024-06-18 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000593290 | SCV001132409 | likely pathogenic | GNE myopathy | 2015-03-02 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000593290 | SCV002075664 | pathogenic | GNE myopathy | 2020-09-10 | no assertion criteria provided | clinical testing |